Loading...
Market
Will semaglutide reduce Alzheimer's risk by 30% in a study by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Publication of major peer-reviewed study results
Story
Studies Show Semaglutide Benefits for Type 2 Diabetes, Knee Pain Reduction by 50%
Nov 7, 2024, 11:00 AM
Recent studies have highlighted the significant health benefits of semaglutide, a GLP-1 receptor agonist, for adults with type 2 diabetes and other conditions. Semaglutide was found to significantly lower the risk of Alzheimer's disease compared to other antidiabetic medications. Additionally, it reduced kidney and cardiovascular disease events in type 2 diabetics and improved obesity-related heart failure with preserved ejection fraction in a placebo controlled trial. In a post hoc analysis, treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation compared to a placebo. A separate study indicated that weekly self-injections of semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.
View original story
Similar markets
Yes • 50%
No • 50%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%